The Patent Finder

Perseus Proteomics Inc.

12 patents currently held · Updated Nov 22, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 13, 2027
    The maintenance fee for Novel Monoclonal Antibody, and Use Thereof (US 9,155,805) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
  • 1 fee due Oct 9, 2027
    The maintenance fee for Composition Containing Buffer (US 11,951,168) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
  • 1 fee due Nov 3, 2027
    The maintenance fee for Anti-CDH3 antibody having high internalization capacity (US 9,328,160) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 24, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,388,249Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same
In force
 · USPTO record
In forceUSPTO record
US 9,155,805Novel Monoclonal Antibody, and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,328,160Anti-CDH3 antibody having high internalization capacity
In force
 · USPTO record
In forceUSPTO record
US 9,764,041Drug conjugate comprising anti-CDH3 (P-cadherin) antibody
In force
 · USPTO record
In forceUSPTO record
US 9,598,496Antibody capable of specifically recognizing transferrin receptor
In force
 · USPTO record
In forceUSPTO record
US 9,593,165Antibody capable of specifically recognizing transferrin receptor
In force
 · USPTO record
In forceUSPTO record
US 9,644,028Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof
In force
 · USPTO record
In forceUSPTO record
US 10,030,071Antibody which specifically reacts with human integrin A6B4
In force
 · USPTO record
In forceUSPTO record
US 11,951,168Composition Containing Buffer
In force
 · High confidence
In forceHigh confidence
US 12,752,008Composition Containing Buffer
In force
 · Low confidence
In forceLow confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 3 patents in force now held by others · 14 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 6 abandoned · 3 no status recorded

Showing 1 to 10 of 13, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/857,526Apr 17, 2023Pending
18/686,256Ros (REACTIVE Oxygen Species) Production Enhancing AgentAug 26, 2022Pending
18/030,534Method for Determining Medicinal Effect or Sensitivity of Anti-Transferrin Receptor AntibodyOct 8, 2021Pending
17/295,263Agent for Inhibiting Iron Uptake into CellsNov 19, 2019Pending
14/913,613Anti-Influenza Virus Neutralizing AntibodyAug 20, 2014Abandoned
14/307,589Jun 18, 2014No status recorded
13/886,936Highly Effective Anti-Cadherin Antibody for Induction of Antibody-Dependent Cellular Cytotoxicity in VivoMay 3, 2013Abandoned
12/964,077Dec 9, 2010No status recorded
12/298,151Therapeutic Agents for Alzheimer's Disease and CancerApr 23, 2007Abandoned
11/584,793Oct 20, 2006Abandoned
10 of 13 applications shown.
Pro members see all 13 published applications.
Pro members: see all 13 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited